RET-PTC1 rearrangement
|
Thyroid Gland Papillary Carcinoma
|
RET-PTC1 rearrangement
|
Thyroid Gland Papillary Carcinoma
|
MK-2206 Sensitive: D – Preclinical
|
MK-2206 Sensitive: D – Preclinical
|
RET-PTC1 rearrangement
|
Thyroid Gland Papillary Carcinoma
|
RET-PTC1 rearrangement
|
Thyroid Gland Papillary Carcinoma
|
dasatinib + CI-1040 Sensitive: D – Preclinical
|
dasatinib + CI-1040 Sensitive: D – Preclinical
|
RET-PTC1 rearrangement
|
Thyroid Gland Papillary Carcinoma
|
RET-PTC1 rearrangement
|
Thyroid Gland Papillary Carcinoma
|
dasatinib Sensitive: D – Preclinical
|
dasatinib Sensitive: D – Preclinical
|
RET-PTC1 rearrangement
|
Thyroid Gland Papillary Carcinoma
|
RET-PTC1 rearrangement
|
Thyroid Gland Papillary Carcinoma
|
cabozantinib capsule Sensitive: D – Preclinical
|
cabozantinib capsule Sensitive: D – Preclinical
|
RET-PTC1 rearrangement
|
Thyroid Gland Papillary Carcinoma
|
RET-PTC1 rearrangement
|
Thyroid Gland Papillary Carcinoma
|
CI-1040 + SU6656 Sensitive: D – Preclinical
|
CI-1040 + SU6656 Sensitive: D – Preclinical
|
RET-PTC1 rearrangement
|
Thyroid Gland Papillary Carcinoma
|
RET-PTC1 rearrangement
|
Thyroid Gland Papillary Carcinoma
|
CI-1040 + PP2 Sensitive: D – Preclinical
|
CI-1040 + PP2 Sensitive: D – Preclinical
|
RET-PTC1 rearrangement
|
Thyroid Gland Papillary Carcinoma
|
RET-PTC1 rearrangement
|
Thyroid Gland Papillary Carcinoma
|
CI-1040 Sensitive: D – Preclinical
|
CI-1040 Sensitive: D – Preclinical
|
RET-PTC1 rearrangement
|
Thyroid Gland Papillary Carcinoma
|
RET-PTC1 rearrangement
|
Thyroid Gland Papillary Carcinoma
|
AZD1480 Sensitive: D – Preclinical
|
AZD1480 Sensitive: D – Preclinical
|